Tone mix
Week by week 52 weeks
Share of OKYO Pharma Limited Ordinary Shares's 196 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Feb 17, 2025 · tone 0OKYO Pharma (NASDAQ:OKYO) & CG Oncology (NASDAQ:CGON) Head-To-Head Contrast-80
- Week of Aug 4, 2025 · tone 0OKYO Pharma-77
- Week of Mar 3, 2025 · tone 0OKYO Pharma Limited (NASDAQ:OKYO) Short Interest Update-72
- Week of Mar 17, 2025 · tone 0OKYO Pharma Limited (NASDAQ:OKYO) Short Interest Update-69
- Week of May 19, 2025 · tone 0OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit-67
- Week of Jul 13, 2026 · tone -25OKYO Pharma (NASDAQ:OKYO) Price Target Cut to $5.00 by Analysts at HC Wainwright-63
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about OKYO Pharma Limited Ordinary Shares in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 0 | No headlines |
| Last 30 sessions | 6 | +80 |
| Last 90 sessions | 44 | +20 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Wednesday, October 7, 2026
3 headlines, average tone +94: 3 positive, 0 neutral and 0 negative. Showing all 3.
- www.proactiveinvestors.com · 1 outletOKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drugPositive
- www.rttnews.com · 1 outletOKYO Pharma Begins Phase 3 Trial Of Urcosimod For Neuropathic Corneal PainPositive
- www.proactiveinvestors.com · 1 outletOKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal PainPositive
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug | www.proactiveinvestors.com | 1 | Positive |
| OKYO Pharma Begins Phase 3 Trial Of Urcosimod For Neuropathic Corneal Pain | www.rttnews.com | 1 | Positive |
| OKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain | www.proactiveinvestors.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 6, 2026
2 headlines, average tone +100: 2 positive, 0 neutral and 0 negative. Showing all 2.
- www.manilatimes.net · 1 outletOKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal PainPositive
- www.investegate.co.uk · 1 outletOKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain | Company AnnouncementPositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain | www.manilatimes.net | 1 | Positive |
| OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain | Company Announcement | www.investegate.co.uk | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, September 29, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.investegate.co.uk · 1 outletOKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences | Company AnnouncementNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences | Company Announcement | www.investegate.co.uk | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, September 9, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.investegate.co.uk · 1 outletOKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 | Company AnnouncementNeutral
- www.dailypolitical.com · 1 outletMaven Securities LTD Decreases Position in OKYO Pharma Limited Sponsored ADR $OKYONeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 | Company Announcement | www.investegate.co.uk | 1 | Neutral |
| Maven Securities LTD Decreases Position in OKYO Pharma Limited Sponsored ADR $OKYO | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, September 8, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.investegate.co.uk · 1 outletOKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference | Company AnnouncementNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference | Company Announcement | www.investegate.co.uk | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about OKYO Pharma Limited Ordinary Shares, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.